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Summary 
 
The Diabetes Remission Clinical Trial reported return and persistence of non-diabetic blood 
glucose control in 46% of people with type 2 diabetes of up to 6 years duration. Detailed 
metabolic studies were performed on a subgroup (intervention n=58; control n=23). In the 
intervention group, liver fat content decreased (16.0±1.3% to 3.1±0.5%, p<0.0001) 
immediately after weight loss. Similarly, plasma triglyceride and pancreas fat content 
decreased whether or not glucose control normalised. Recovery of first phase insulin 
response (0.04[-0.05-0.32] to 0.11 [0.0005-0.51] nmol/min/m2, p<0.0001) defined those 
who returned to non-diabetic glucose control and this was durable at 12 months (0.11 
[0.005-0.81] nmol/min/m2, p=0.0001). Responders were similar to non-responders at 
baseline but had shorter diabetes duration (2.7±0.3 vs. 3.8±0.4 years; p=0.02).  No change 
was observed in the conventionally managed control group. This study demonstrates that 
beta cell ability to recover long term function persists after diagnosis, changing the previous 
paradigm of irreversible loss of beta cell function in type 2 diabetes. 
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Introduction 
 
Type 2 diabetes now affects at least one in ten US adults, and 422 million worldwide 
(Menke et al., 2015; WHO, 2016). It has long been regarded as an inevitably 
progressive, lifelong condition. However, the Diabetes Remission Clinical Trial 
(DiRECT) has demonstrated that nearly half of those with early (< 6 years) type 2 
diabetes can be returned to long term non-diabetic glucose control using an 
effective method to achieve and maintain substantial weight loss (Lean et al., 2017). 
The initial period of weight loss was followed by weight maintenance and the data 
were reported at 12 months. This population-based study built upon the results of 
earlier small studies which revealed the detailed physiological basis of the transition 
from type 2 diabetes to normal (Lim et al., 2011; Petersen et al., 2005; Steven et al., 
2016a; Steven et al., 2016b). However, whether these mechanisms operate in all 
individuals with type 2 diabetes and the critical factor(s) that determine the capacity 
to return to non-diabetic glucose metabolism remain uncertain. 
 
During a very low calorie diet in type 2 diabetes an initial study showed that liver fat 
content rapidly decreased, with normalisation of hepatic insulin sensitivity within 7 
days (Lim et al., 2011). Over an 8 week period, pancreas fat content decreased more 
slowly, as first phase insulin response gradually returned. A follow up study 
demonstrated that as duration of type 2 diabetes increased beyond 10 years, the 
possibility of restoring beta cell function decreased (Steven et al., 2016a). These 
observations led to a simplified view of the aetiology of type 2 diabetes (Taylor, 
2013), consistent with earlier observations (Henry et al., 1986; Wing et al., 1987), in 
that linked but distinct mechanisms in liver and pancreas appeared to explain the 
condition.  Recently, the molecular basis of the liver abnormalities in type 2 diabetes 
has been clarified (Perry et al., 2018).  In addition, a major decline in beta cell 
function is necessary before type 2 diabetes develops. In the last few years, 
metabolic stress-induced beta cell de-differentiation and subsequent re-
differentiation with significant weight loss have been demonstrated, potentially 
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explaining any return from type 2 diabetes to normal glucose tolerance (Cinti et al., 
2016; Pinnick et al., 2010; Talchai et al., 2012; White et al., 2016).  A larger study was 
required to determine the extent to which this explains common type 2 diabetes. 
Detailed pathophysiologic studies were carried out in a geographically pre-defined 
sub-group of DiRECT participants. These were designed to test the hypothesis that 
there would be differences between those who did or did not return to non-diabetic 
glucose control in some or all of the factors previously identified as underlying type 2 
diabetes. We have examined liver fat content, liver export of triglyceride, pancreas 
fat content and beta cell function in type 2 diabetes during conventional therapy, 
after weight loss and after 12 months of weight maintenance.  
 
Results and Discussion 
  
Baseline characteristics 
Responders, who returned to non-diabetic glucose control after weight loss, and 
non-responders, who did not, were similar in age, weight and sex (Table 1; Figure 
3A). Responders had a non-significantly lower fasting plasma glucose than non-
responders (148.9±6.8 vs. 167.8±11.9 mg/dl, p=0.18; Figure 3B), and HbA1c was 
7.4±0.2 vs. 7.9±0.2% respectively (p=0.04; Figure 3C). At baseline, liver fat in the 
whole intervention group was 16.0±1.3% and was not significantly different in 
responders and non-responders (16.7±1.5 vs. 14.5±2.6% respectively; p=0.47). There 
was no significant difference at baseline between responders and non-responders in 
VLDL1-TG production (560.7±30.9 vs. 581.1±52.1 mg/kg/day, p=0.74; Figure 4C) or 
total plasma triglyceride (1.84±0.13 vs. 1.91±0.25mmol/l; p=0.76).  The non-
responders had a longer duration of diabetes (2.7±0.3 vs. 3.8±0.4 years; p=0.02), 
lower fasting plasma insulin (108.3±10.0 vs. 77.2±8.5pmol/l; p=0.02) and lower 
plasma ALT (34.1±2.8 vs. 26.3±2.6 pmol/l; p<0.05).  Data on the whole intervention 
group compared with the conventionally treated control group are shown in Table 3.   
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Lower fasting plasma insulin levels and lower plasma ALT in individuals with type 2 
diabetes who cannot achieve non-diabetic plasma glucose levels despite adequate 
weight loss have previously been observed in a group with up to 23 years duration of 
diabetes (Steven et al., 2016a). In that study, longer duration was clearly associated 
with inability to achieve remission of diabetes. There was an evident failure at 
baseline to maintain fasting plasma insulin levels in the non-responders which was 
accompanied by lower hepatic fat levels. This is consistent with a slowing of insulin-
driven de novo lipogenesis as the beta cell defect advances. Type 2 diabetes of more 
than 8 years duration was observed to be associated with considerably lower plasma 
ALT (Steven et al., 2016b). In contrast, the present study focussed upon the first 6 
years of type 2 diabetes and within this shorter time span only a modest, non-
significant difference in liver fat levels was observed between responders and non-
responders. Nonetheless, plasma ALT levels were 23% lower in non-responders 
(p<0.05, Table 1), suggesting that the metabolic stress on the hepatocyte had 
diminished.  
 
Weight 
During the weight loss phase, weight decreased in responders (100.6±2.6 to 
84.4±2.1kg; p<0.0001; n=40) and in non-responders (102.1±4.4 to 88.7±4.4kg; 
p<0.0001; n=18; Figure 3A). The change during the weight loss phase did not differ 
significantly between groups (-16.2 ±1.2 vs. -13.4 ±1.4kg; p=0.14; Table 2).  
Between the end of weight loss and 12 months (weight maintenance phase), four 
responders failed to maintain remission, and nine participants dropped out of the 
total Intervention group. Paired data for the weight maintenance phase were thus 
available on 29 responders and 16 non-responders (Figure 1). No participants 
defined as non-responders after weight loss achieved remission during the weight 
maintenance phase. Weight in responders increased by 3.3±0.8kg to 86.2±3.0 kg 
(p<0.0001). Over the same period weight in non-responders increased by 4.9±0.8kg 
to 92.5±4.6 kg but stayed lower than baseline (p<0.0001). By 12 months the overall 
change was greater in the responders (-14.1±1.5 vs. -9.4±1.3kg; p=0.02). 
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Glucose control 
Weight loss lowered fasting plasma glucose from 148.9±6.8 to 102.2±2.2 mg/dl 
(p<0.0001) in responders, and had no significant effect in non-responders (167.8 
±11.9 to 158.9 ±10.9 mg/dl; p=0.47; Figure 3B). By 12 months there was no 
significant further change in either group (responders: 102.4±2.3 mg/dl; non-
responders: 152.0±7.9 mg/dl; Figure 3B).  
HbA1c decreased in responders (to 5.9±0.1%; p<0.0001), but not in non-responders 
(8.0±0.4 %, p=0.67; Figure 3C). At 12 months, HbA1c did not change further in either 
group so that differences were maintained (5.8±0.1 vs. 7.6±0.2 %, p<0.0001; Table 
2). 69% of the Intervention group (40/58) achieved non-diabetic blood glucose 
control after weight loss, and 64% at 12 months (29/45). 
 
Liver fat 
Liver fat content decreased after weight loss in both groups (responders: to 
3.3±0.6%; p<0.0001; non-responders: to 2.6±0.5%; p<0.0001; Figure 4A). The change 
in liver fat was similar (-13.4±1.4 vs. -11.9±2.4%, p=0.60; Table 2). At 12 months, liver 
fat in responders was 3.0±0.6% and in non-responders 6.1±1.9% (p=0.11 and p=0.04 
respectively compared with post-weight loss). The increase in liver fat in the weight 
maintenance phase was related to degree of weight gain. Those who gained less 
than the mean weight gain of the responder group (3.3kg) had no change in liver fat 
(3.2±1.1 vs. 3.2±1.0%; p=0.95; n=16). In contrast, in those who gained more than 
3.3kg, there was a resultant increase in liver fat (1.5±0.3 vs. 2.8±0.5%; p=0.03; n=12). 
In those randomised to the conventionally treated control group, there was no 
significant change in liver fat throughout the study (Figure 4A; Table 3).  
The importance of high levels of liver fat in the pathogenesis of type 2 diabetes is 
now recognised (Bril and Cusi, 2017; Petersen et al., 2005; Shibata et al., 2007; 
Steven et al., 2016b; Taylor, 2013). Raised liver fat levels are associated with hepatic 
insulin resistance, inadequate suppression of hepatic glucose production and hence 
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increased fasting plasma glucose (Petersen et al., 2005; Ravikumar et al., 2008; 
Seppala-Lindroos et al., 2002). Excess diacylglycerol has a profound effect in 
activating PKCε which inhibits the signalling pathway from the insulin receptor to 
IRS-1, the first post-receptor step in intracellular insulin action (Samuel et al., 2010). 
So, under circumstances of chronic energy excess, a raised level of intracellular 
diacylglycerol specifically prevents normal insulin action, and hepatic glucose 
production fails to be controlled. High-fat feeding of rodents brings about raised 
levels of diacylglycerol, PKCε activation and insulin resistance (Samuel et al., 2004), 
and these changes have recently been shown to reverse after 3 days on a very low 
calorie diet (Perry et al., 2018). The relationship between raised diacylglycerol, PKCε 
activation and hepatic insulin resistance leading to increased hepatic glucose output 
was clearly demonstrated in this recent study. In obese humans, intrahepatic 
diacylglycerol concentration has been shown to correlate with hepatic insulin 
sensitivity (Kumashiro et al., 2011; Magkos et al., 2012). It must be noted that raised 
diacylglycerol and PKCε activation are corrected early during calorie restriction and 
before major weight change (Lim et al., 2011; Perry et al., 2018). This should not  be 
interpreted to indicate that the more gradually occurring weight loss is not necessary 
for long term normalisation. The mechanisms underlying hepatic insulin resistance 
are now established, and the present observations demonstrate the complete 
reversibility of the liver abnormalities of human type 2 diabetes.  
 
Lipid metabolism 
In responders, VLDL1-TG production decreased after weight loss (to 413.6±25.8 
mg/kg/day, p<0.0001; Figure 4C). In non-responders, there was a non-significant fall 
(to 521.8 ±41.9 mg/kg/day; p=0.28). The change during weight loss was not 
significantly different between responders and non-responders (-147.2±33.8 vs. -
59.2±52.7; p=0.17). VLDL1-TG production rate did not change during the weight 
maintenance phase in responders (at 12 months: 437.5±22.4 mg/kg/day, p=0.12) but 
increased in non-responders (to 649.6±67.0 mg/kg/day, p=0.008).  
Plasma VLDL1-TG concentration decreased in responders after weight loss 
(0.69±0.07 to 0.44±0.06 mmol/l, p=0.001, Figure 4E), followed by a small increase 
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during weight maintenance (to 0.49±0.08 mmol/l, p=0.04; Figure 4E). There was no 
significant change in non-responders after weight loss (0.73±0.11 to 0.55±0.12 
mmol/l, p=0.12) nor during the weight maintenance phase (to 0.64±0.12 mmol/l, 
p=0.12). 
Total plasma triglyceride (largely chylomicrons plus VLDL-TG) fell similarly in 
responders and non-responders after weight loss (1.84±0.13 to 1.30 ±0.13 mmol/l, 
p<0.0001 and 1.91±0.25 to 1.24 ±0.14 mmol/l respectively, p=0.002, Figure 4B). This 
remained stable at 12 months (responders: to 1.24±0.12 mmol/l, p=0.43; non-
responders: to 1.39±0.21 mmol/l, p=0.52). In those randomised to control, there was 
no significant change in any parameter of lipid metabolism during the study (Table 
3).  
The series of studies which led to DiRECT was initiated to test the twin cycle 
hypothesis (Taylor, 2008). This described vicious cycles within the liver and pancreas, 
respectively ratcheting up hepatic insulin resistance and beta cell dysfunction. 
Critically, it postulated that these cycles were linked by elevated insulin driving 
increased de novo lipogenesis and hepatic VLDL1-TG export. The increased exposure 
of beta cells to fat metabolites was postulated to lead ultimately to beta cell failure. 
VLDL1-TG is a major determinant of plasma triglyceride (Hiukka et al., 2005) and 
plasma concentration is proportional to liver fat content (Adiels et al., 2006). The 
dramatic and sustained normalisation of liver fat content in the present study was 
associated with a fall in both VLDL1-TG production rate and plasma levels. The fall 
was most pronounced in responders and with the continuing normoglycemia and 
low liver fat content, both production rate and plasma VLDL1-TG concentration 
remained significantly lower than baseline at 12 months. In non-responders, the 
modest weight gain during weight maintenance was followed by a significant rise in 
VLDL1-TG production rate even though the fasting plasma VLDL1-TG and total 
triglyceride concentrations remained lower than baseline. This suggests that non-
responders may exhibit a different relationship between the two major components 
of plasma triglyceride - chylomicron and VLDL1-TG. This may possibly relate to 
different hepatic insulin sensitivity or plasma glucose levels in responders compared 
to non-responders. Although the major source of fatty acids supplying VLDL1-TG 
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export is from adipose derived fatty acids (around 60%), the contribution of de novo 
lipogenesis to VLDL1-TG is much greater when liver triglyceride levels are raised 
(Donnelly et al., 2005). In non-obese individuals this process accounts for only a 
small proportion of the fatty acids of VLDL1-TG, whereas in NAFLD it accounts for up 
to 26% (Lambert et al., 2014; Timlin et al., 2005).  The present observations on 
change in VLDL1-TG and total plasma triglyceride are consistent with the predictions 
of the twin cycle hypothesis. 
 
Pancreas fat 
Pancreas fat did not differ significantly between responders and non-responders at 
baseline (8.7±0.4 vs. 7.9±0.6%; p=0.25, Figure 4D). Weight loss produced a similar 
fall in intrapancreatic fat in both groups (responders: to 7.8±0.4%; p<0.0001 and 
non-responders: to 7.1±0.5%; p=0.004). There was no significant difference in extent 
of change between the two groups (-0.90±0.17 vs. -0.78±0.23%; p=0.67; Table 2). 
During the weight maintenance phase, it remained stable in both groups (7.9±0.4% 
and 6.8±0.4% in responders and non-responders, respectively). There was no change 
in pancreas fat in the control group (Table 3).  
The magnetic resonance method quantifies fat content of both exocrine and 
endocrine pancreas, and the relationship of this to islet fat content and exposure 
must be considered. In rodents, beta cell triglyceride content is directly related to 
total intrapancreatic fat content, and these parameters change in step (Lee et al., 
2010). In vivo measurement of intrapancreatic fat content in human studies during 
an 8 week period of calorie restriction in type 2 diabetic humans is concordant with 
the rodent observations, and also matches the gradual return of first phase insulin 
secretion in that study (Lim et al., 2011). The change in total intrapancreatic fat is 
not seen during equivalent loss of weight in non-diabetic humans (Steven et al., 
2016b), implying a specific excess of intracellular triglyceride within both exocrine 
and endocrine cells of the pancreas in type 2 diabetes. In addition to this 
endogenous pool, the ongoing exposure of beta cells to excess fatty acid delivered 
from plasma VLDL1-TG and chylomicrons will contribute to the metabolic load 
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experienced by the beta cell. Intrapancreatic triglyceride content and lipid supply 
were decreased in both responders and non-responders.  
 
Beta cell function 
Fasting plasma insulin decreased in both groups during weight loss (responders: 
108.3±10.0 to 38.7±4.4 pmol/l; p<0.0001; non-responders 77.2±8.5 to 35.5±5.3 
pmol/l; p=0.0002, Figure 4F). Because of the higher baseline level in responders, 
there was a greater decrease in this group (-69.7±9.3 vs. -41.7 ±5.8 pmol/l; p<0.01). 
At 12 months fasting plasma insulin remained steady in both groups (responders: 
41.1±5.5 pmol/l, p=0.41) and non-responders: 45.8±8.4 pmol/l, p=0.40).  
First phase insulin secretion increased in responders after weight loss from 0.04[-
0.05-0.32] to 0.11 [0.0005-0.51] nmol/min/m2 (p<0.0001). Whereas no change was 
observed in the non-responders (0.02[-0.07-0.13] to 0.01[-0.04-0.05] nmol/min/m2; 
p=0.96; Figure 5A; Table 2). In the responders, increased first phase insulin secretion 
was maintained during the weight maintenance phase (to 0.11[0.005-0.81] 
nmol/min/m2; p=0.97). Between baseline and 12 months the change was highly 
significant (p=0.0001). 
There was a gradual increase in maximal insulin secretion in responders after weight 
loss that became significant at 12 months (0.62[0.13-1.95] to 0.94 [0.25-2.69] 
nmol/min/m2; p<0.04 compared with baseline; Figure 5B). It remained unchanged in 
non-responders.  
First phase and total insulin secretion rates remained unchanged in the control 
group throughout the study (Table 3).  
It was established many years ago that chronic in vitro exposure of beta cells to 
triglyceride or fatty acids decreases ability to respond to an acute increase in glucose 
levels (Lee et al., 1994) and the concept that excess fat can impair beta cell function 
is not new (McGarry, 2002; Unger, 1995). In the ZDF rat, the onset of hyperglycemia 
is preceded by a rapid increase in pancreatic fat (Lee et al., 1994) and diabetes is 
completely preventable by restriction of food intake (Ohneda et al., 1995). Chronic 
exposure of human beta cells to lipid excess brings about decreased function (Zhou 
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and Grill, 1995). Early studies demonstrated the ultrastructural damage brought 
about even by relatively low concentrations of saturated fatty acids (Pinnick et al., 
2010; Pinnick et al., 2008), and this endoplasmic reticulum stress has been identified 
in other in vivo studies of type 2 diabetes (Huang et al., 2007; Laybutt et al., 2007). 
Clearly, hyperglycemia cannot explain the initiation of beta cell stress in type 2 
diabetes, but once the increased glucose levels are added to lipid-induced stress the 
increased glucose supply will compound and perpetuate the metabolic insult 
(Bensellam et al., 2012; Poitout et al., 2010; Weir et al., 2013). Loss of fully 
differentiated beta cell phenotype is now recognised as the most likely mechanism 
underlying type 2 diabetes (Bensellam et al., 2018; Brereton et al., 2014; Spijker et 
al., 2015; Talchai et al., 2012; Wang et al., 2014; White et al., 2013). Very recent 
work has identified markers of dedifferentiation in the islets from people with type 2 
diabetes (Cinti et al., 2016). In the non-responders, lower baseline fasting plasma 
insulin levels, lower ALT levels and higher HbA1c are consistent with a more 
advanced, irreversible stage of beta cell dysfunction.   
A potential alternative explanation could be that the non-responders have a 
different etiology of diabetes, in which non-lipid driven defects in beta cells are more 
important. However, the responders and non-responders were similar in 
anthropological characteristics at baseline, and exhibited the same abnormalities of 
grossly elevated liver fat content and all other metabolic abnormalities. Even though 
the DiRECT cohort was selected to have duration of type 2 diabetes of less than 6 
years, the non-responders had a modestly longer recorded duration of disease.   
It is established that the natural history of beta cell decline follows widely different 
time courses between individuals (Harrison et al., 2012; Turner et al., 1999), but this 
is the first time that a difference in disease duration has been shown to relate to the 
capacity for redifferentiation during the first 6 years of type 2 diabetes. This 
observation carries potentially important implications for the initial clinical approach 
to management. At present, the early management of type 2 diabetes tends to 
involve a period of adjusting to the diagnosis plus pharmacotherapy with lifestyle 
changes which in practice are modest. The present data suggest that substantial 
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weight loss at the time of diagnosis may be more appropriate to prevent ongoing 
loss of beta cell capacity.   
  
Substrate oxidation 
The return to non-diabetic glucose control was accompanied by an increase in basal 
glucose oxidation rates and a fall in basal lipid oxidation rates (Table 1). These 
changes were not fully developed immediately after weight loss, but maximal at 12 
months. The glucose oxidation rates in responders increased from 1.27±0.12 at 
baseline to 1.44±0.14 and to 2.00±0.19 mg/kg/min after weight loss and weight 
maintenance respectively (p<0.0001 between baseline and 12 months). This was 
reflected in a greater increase in responders between baseline and 12 months 
compared to non-responders (0.75 ±0.18 vs. -0.11±0.23 mg/kg/min; p=0.006; Table 
2).  Conversely, lipid oxidation rates decreased in responders from 0.96±0.05 to 
0.87±0.06 (p<0.28) and to 0.64±0.09 mg/kg/min; p<0.01) with a greater decrease 
than in non-responders over the same period (-0.32±0.08 vs. -0.05±0.09 mg/kg/min; 
p<0.04). There were no significant changes in substrate oxidation rates in the non-
responders (Table 1).  
 
Limitations 
Reflecting the population of Tyneside, 98% of participants were white, and 
comparable studies in other ethnic groups are required. However, socio-economic 
deprivation was well represented, with 39% being from the lowest two quintiles for 
deprivation (Taylor et al., 2017). At baseline, participants were taking a range of anti-
diabetic medications, reflective of current practice. Although people on insulin 
therapy were excluded from this primary care based study for practical reasons, 
prior insulin therapy is not a major determinant of diabetes remission following 
major weight loss (Panunzi et al., 2016). The study participants were not followed 
closely in a specialist centre but lived normal lives and reviewed by different primary 
care nurse, possibly introducing some heterogeneity. This could be interpreted to 
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indicate generalisability of the conclusions. Finally, the observations relate to only 12 
months of observation, and 24 month follow up is underway (Taylor et al., 2017).   
 
Conclusions 
 
This study demonstrates the physiologic changes associated with the return to 
normal glucose homeostasis in type 2 diabetes. It also quantifies the responses to 
weight loss in those who returned to normal glucose control compared with those 
who did not and shows most marked differences between these two groups to be in 
their ability to recover first phase insulin response.  An average decrease in body 
weight of 15% was achieved by a structured programme delivered by Primary Care 
staff. This brought about profound changes in lipid metabolism, irrespective of 
response in terms of glucose control. The greatest change was in liver fat content 
which fell from high levels to normal in the whole Intervention group at 12 months. 
Fall in plasma levels of VLDL1-TG was accompanied by fall in intrapancreatic fat 
content. All changes in lipid metabolism and intra-organ lipid remained steady over 
12 months if weight loss was maintained, but, critically, only the responders 
demonstrated early and sustained improvement in beta cell function as measured by 
gold standard methodology, with difference at 12 months being striking.  In 
summary, weight loss in early type 2 diabetes brings about similar correction of 
intra-organ fat content in all, but the defect in those who do not return to non-
diabetic glucose control appears intrinsic to the beta cell.  
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Figure Legends 
 
Figure 1: CONSORT diagram of study randomization and sample size 
In the Intervention group 6 subjects withdrew during the weight loss phase and 7 during 
weight maintenance. To permit the paired analysis within each group, 4 subjects were 
excluded due to reversion to diabetic status. 
In the Control group of type 2 diabetes followed over time, 1 subject withdrew and other 2 
subjects were excluded due to dietary weight loss and remission of diabetes. During the 
weight maintenance phase, 3 subjects withdrew.   
 
Figure 2: Study protocol 
Participants were randomized to receive a low calorie diet (Intervention) or to continue with 
their normal medication (Control).  This was lasted for an average of 4 months then 
followed by Stepped Food Reintroduction (SFR) and weight maintenance.  
 
 
Figure 3: Changes in weight and glucose control 
Change in weight (A), fasting plasma glucose (B), and HbA1c (C) within the study groups 
between baseline, post weight loss (5 months), and 12 months.  Data are shown as mean 
±SEM. Responders were presented as solid line, non-responders dotted black line, and 
control as grey dotted line. 
***P<0.0001 vs. baseline (responders); †††P<0.0001 vs. baseline (non-responders) 
###P<0.0001 vs. 5 months (responders); ‡‡‡P<0.0001 vs. 5 months (non-responders) 
 
 
Figure 4: Induced changes in lipid metabolism and fasting plasma insulin 
Change in liver fat (A), total plasma triglycerides (B), hepatic VLDL1-TG production (C), 
intrapancreatic fat (D), fasting plasma VLDL1-TG (E), and fasting plasma insulin (F) between 
baseline, post weight loss (5 months), and 12 months. Data are shown as mean ±SEM. 
Responders were presented as solid line, non-responders dotted black line, and control as 
grey dotted line. 
**P<0.01 vs. baseline, ***P<0.0001 vs. baseline (responders) 
††P<0.01 vs. baseline, †††P<0.0001 vs. baseline (non-responders) 
#P<0.05 vs. 5 months (responders); ‡P<0.05 vs. 5 months (non-responders); ‡‡P<0.01 vs. 5 
months (non-responders) 
 
Figure 5: Induced changes in beta cell response to glucose stimulation 
Median (range) first phase insulin response (A) and maximal insulin secretion (B) at baseline, 
post weight loss (5 months), and 12 months.  Responders - a black box; non-responders - 
dark grey box; control - light grey box. 
*P<0.05 vs. baseline (responders), ***P<0.0001 vs. baseline (responders) 
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*P<0.05 vs. baseline, **P<0.01 vs. baseline, ***P<0.0001 vs. baseline, # P<0.05 vs. 5 months, ## P<0.01 vs. 5 months, ### P<0.0001 vs. 5 
months, † P<0.05 responders vs. non-responders, †† P<0.01 responders vs. non-responders. Paired data were presented (baseline to post-
weight loss or baseline /post weight loss to 12 months). 
 Responders  Non-responders  
Baseline  
(n=40) 
Post-weight                                  
loss (n=40) 
12 months  
      (n=29) 
Baseline 
(n=18) 
Post-weight                 
loss (n=18) 
 
12 months 
 (n=16) 
BMI (kg/m2) 34.9±0.7 29.4±0.6*** 29.6±0.8***### 
 
35.7±1.2 31.1±1.3*** 32.4±1.4***### 
Age (Year) 
 
Sex (F/M) 
 
53.0±1.2 
 
17/23 
- 
 
- 
- 
 
- 
53.3±1.9 
 
9/9 
- 
 
- 
- 
 
- 
Diabetes duration (years) 2.7±0.3 - - 3.8±0.4† - - 
VLDL1-TG pool(mg) 2445.9±267 1258.4±168*** 1461.7±240**## 2775.4±505 1866.4±432* 2234.1±570 
Fasting NEFA (mmol/l) 0.56±0.03 0.55±0.03 0.51±0.03 0.66±0.04 0.59±0.05 0.61±0.04 
Alanine Aminotransferase 
(ALT) (U/l) 
34.1±2.8 - 17.1±1.0*** 26.3±2.6† - 18.3±2.0** 
Cholesterol (mmol/l) 4.3±0.2 - 4.3±0.2 4.1±0.3 - 4.0±0.2 
HDL (mmol/l) 1.09±0.05 - 1.23±0.08** 0.99±0.05 - 1.11±0.06* 
Ketone (mmol/l) 0.19±0.02 0.29±0.04** 0.26±0.03* 0.18±0.02 0.20±0.02 0.24±0.04 
Lipid oxidation (mg/kg/min) 0.96±0.05 0.87±0.06 0.64±0.09***## 0.84±0.08 0.89±0.11 0.83±0.07 
Glucose oxidation 
(mg/kg/min) 
1.27±0.12 1.44±0.14 2.0±0.19***## 1.48±0.17 1.19±0.21 1.31±0.20† 
Resting Energy Expenditure  
(kcal/day) 
1996.5±57.0 
 
1647.1±48.1*** 
 
1696.4±67.3***# 
 
1981.7±108.0 
 
1641.1±89.5** 
 
1733.2±109.5** 
 
Table 1: Anthropometric, clinical and metabolic features of responders and non-responders before and after intervention 
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Table 2: Metabolic changes in responders and non-responders during weight loss, weight maintenance and from baseline to 12 months 
 Baseline to post-weight loss Post weight loss to 12 months Baseline to 12 months 
Δ change  Responders 
    (n=40) 
Non-responders 
  (n=18) 
Responders 
    (n=29) 
Non-responders 
  (n=16) 
Responders 
    (n=29) 
Non-responders 
  (n=16) 
Weight (kg) -16.2±1.2 -13.4±1.4  3.3±0.8 4.9±0.8 -14.1±1.5 -9.4±1.3* 
Fasting plasma glucose (mg/dl) -46.6 ±7.3 -8.9±12.0** 1.6±2.6 -3.6±11.2 -47.9±8.7 -21.3±7.8* 
HbA1c (%) -1.5±0.2 0.2±0.4*** -0.1±0.05 -0.4±0.35 -1.6±0.2 -0.4±0.2*** 
Liver fat (%) -13.4±1.4 -11.9±2.4 0.6±0.3 3.6±1.6 -13.5±1.9 -9.7±2.1 
VLDL1-TG production 
(mg/kg/day) 
-147.2 ±33.8 -59.2±52.7 43.1 ±26.7 155.8±50.8 -119.2 ±39.0 72.2±73.6* 
Plasma VLDL1-TG (mmol/l) -0.26±0.07 -0.19±0.12 0.10±0.05 0.16±0.10 -0.21±0.09 -0.04±0.08 
VLDL1-TG pool (mg) -1187.5 ± 245.9 -909.0 ± 385.4 391.5 ± 149.0 659.1 ± 364.7 -993.7 ± 303.8 -313.5 ± 301.1 
Total plasma TG (mmol/l) -0.54±0.12 -0.67±0.19 0.08±0.10 0.13±0.19 -0.58±0.18 -0.57±0.13 
Fasting plasma insulin (pmol/l) -69.7±9.3 -41.7±5.8* 7.2±3.9 10.7±5.2 -65.3±12.1 -32.7±5.7* 
Pancreas fat (%) 
 
-0.90±0.17 -0.78±0.23 -0.14±0.28 0.17±0.23 -1.31±0.28 -0.74±0.27 
First phase insulin 
 (nmol/min/m2) 
0.08[-0.17-0.47] -0.002[-0.11-0.06]*** 0.02[-0.32-0.51] -0.01-0.06—0.08] 0.08[-0.30-0.81] -0.004[-0.17-0.11]*** 
Maximal insulin secretion 
(nmol/min/m2) 
0.08[-1.37-2.66] -0.03[-1.80-0.66] 0.09[-2.17-1.81] 0.02[-0.44-0.61] 0.17[-1.24-2.05] 0.06[-1.72-0.86]* 
Glucose oxidation rate 
(mg/kg/min) 
0.17±0.19 -0.29±0.27 0.82±0.22 0.06±0.30* 0.75±0.18 -0.11±0.23** 
Lipid oxidation rate 
 (mg/kg/min) 
-0.09±0.08 0.05±0.13 0.31±0.10 -0.02±0.15 -0.32±0.08 -0.05±0.09* 
*P<0.05 responders vs. non-responders, **P<0.01 responders vs. non-responders, ***P<0.0001 responders vs. non-responders 
Paired data were used to present changes between different phases of the study. 
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Table 3: Comparison of metabolic parameters between Intervention and Control groups  
 
 Intervention  Control  
Baseline 
(n=58) 
5 months 
(n=58) 
12 months  
(n=45) 
Baseline 
(n=23) 
5 months 
(n=23) 
12 months  
(n=20) 
Weight  (kg) 101.1±2.2 85.8±2.0*** 88.4±2.5***### 96.7±2.5 95.8±2.7 95.2±3.2 
HbA1c (%) 7.6± 0.1 6.5± 0.2*** 6.4± 0.2*** 7.4± 0.2 7.8±0.3* 7.2±0.2 
Fasting  plasma glucose (mg/dl) 154.7±6.0 119.8±5.0*** 120.0±4.8*** 149.7±7.6 151.0±8.6 152.6±9.0 
Liver fat (%) 16.0 ±1.3 3.1 ±0.5*** 4.1±0.8***# 9.8±1.7 † 10.6±1.8 9.2±1.9 
VLDL1-TG PR (mg/kg/day) 567.3±26.6 448.4±22.9*** 511.5±31.2**## 491.1±27.6 489.6±40.1 554.3±28.9 
Plasma VLDL-TG (mmol/l)  0.71±0.06 0.47±0.05*** 0.54±0.07*# 0.51±0.09 0.56±0.09 0.61±0.12 
Pancreas fat (%) 8.5±0.3 7.6±0.3*** 7.5±0.3*** 8.1±0.5 8.2±0.5 8.1±0.5 
Fasting plasma insulin (pmol/l) 98.5±7.5    37.7±3.4***  42.8±4.6***## 87.1 ±13.4 77.3±12.4 73.6±14.6 
First phase ins. (nmol/min/m2) 0.03[-0.07-0.32] 0.06[-0.04-0.51]*** 0.06[-0.03-0.81]** 0.02[-0.05-0.29] 0.03[-0.06-0.25] 0.03[-0.05-0.38] 
Maximal insulin (nmol/min/m2) 0.53[0.13-2.35] 0.63[0.01-3.21] 0.63[0.25-2.69] 0.54[0.13-1.76] 0.57[0.26-1.38] 0.56[0.25-1.45] 
 
*P<0.05 vs. baseline, **P<0.01 vs. baseline, ***P<0.0001 vs. baseline. 
# P<0.05 vs. 5 months, ## P<0.01 vs. 5 months, ### P<0.0001 vs. 5 months. 
†  P<0.05 Intervention vs. Control at baseline. 
Paired data were presented (baseline to post-weight loss or baseline/ post weight loss to 12 months). 
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STAR Methods 
 
KEY RESOURCES TABLE 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Instruments and software  
3T Philips Achieva 
scanner 
Philips,  Netherlands SN: 17497 
Six-channel cardiac 
array 
Philips,   Netherlands PN: 453567009711 
Three-point Dixon 
acquisition  
Philips,  Netherlands mDixon 
Balanced Turbo Field 
Echo acquisition 
Philips,  Netherlands BTFE 
Glucose analyzer  Yellow Springs Inc, USA YSI 2300 STAT Plus 
Ultracentrifuge Beckman Coulter Inc, USA Model L7-80 
Low speed centrifuge MSE Ltd., UK Harrier 18/80R 
Low speed centrifuge Scientific Laboratory 
Supplies Ltd, UK. 
Sigma 6K15 
SW 40 Ti rotor Beckman Coulter, Inc, 
USA 
PN: 331302 
Peristaltic pump eBay, China BT100M 
Quark RMR  COSMED, Italy PN:C09074-01-99 
Infusion pump Arcomedical Infusion Ltd, 
UK 
Volumed® VP7000 PVC 
MATLAB MathWorks, UK Version R2013a 
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ImageJ National Institutes of 
Health (NIH), USA 
Version 1.50 
Minitab  Minitab Inc.,  USA Version 17 
MRIcro University of South 
Carolina, USA 
Version 1.40 
Low Calorie Diet 
Liquid formula diet 
(825–853 kcal/day)                                        
Cambridge Weight Plan 
Ltd., UK
N/A 
Laboratory reagents for lipoprotein separation 
Sodium Chloride Sigma-Aldrich, UK Cat No: S9888  
Sodium Bromide 97%  Alfa Aesar, USA Cat No: 14037 
Na2 EDTA VWR International Ltd, 
UK 
Cat No: 100935V 
Sodium Hydroxide VWR International Ltd, 
UK 
Cat No: 102525P 
Ultracentrifuge tubes  SETON SCIENTIFIC, INC, 
USA 
Cat No:7031W 
Glass Pasteur Pipettes VWR International Ltd, 
UK 
Cat No: VWRI 1822 
Clinical reagents for metabolic  
0.9% Sodium Chloride  Fresenius Kabi Ltd, UK Freeflex®  
Intralipid 20%  Fresenius Kabi Ltd, UK Intralipid® 20% 
Intralipid 10%  Fresenius Kabi Ltd, UK Intralipid® 10% 
20% Dextrose  Fresenius Kabi Ltd, UK 20% Dextrose 
Arginine  Martindale 
Pharmaceuticals, UK 
L-Arginine hydrochloride (50%) 
Plasma assays  
Triglyceride  Roche Diagnostics, U.K. Cat No: 05171407 190 
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Insulin ELISA kit  Mercodia AB, Sweden 10-1128-01 
C-peptide ELISA kit Mercodia AB, Sweden 10-1136-01 
HbA1c  Tosoh Bioscience, UK HPLC-923G8 
NEFA enzymatic 
calorimetric kit 
BMG labtech, Germany FLUOstar Omega microplate 
reader 
Ketone meter Abbott Diabetes Care Ltd, 
UK 
Optium Xceed (XCF644-3826) 
Deposited data 
Raw data 
 
Mendeley dataset 
 
doi:10.17632/9k9cgb8mwy.1 
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
All queries should be directed to the lead author, Roy Taylor (roy.taylor@ncl.ac.uk)..  
 
DATA AVAILABILITY 
The dataset of this study is available in Mendeley Data  
(doi:10.17632/9k9cgb8mwy.1).        
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
The metabolic study was nested within the cluster-randomised controlled Diabetes 
Remission Clinical Trial (DiRECT; ISRCTN03267836) (Leslie et al., 2016). Ethical 
approval was obtained from the West of Scotland Ethics Committee, and written 
informed consent was obtained from all participants.  The primary aim of DiRECT 
was to assess the effect of weight loss by low calorie diet on type 2 diabetes 
remission in a routine primary care setting. Individuals with type 2 diabetes living in 
the Tyneside region of England (n=90, 38F/52M, (mean± SD): age 52.8±7.9 years, 
weight 100.2±16.3kg, BMI 34.7±7.4 kg/m2, diabetes duration 3.0±1.7 years, HbA1c 
7.5±1.0 %) were recruited by their general practices (Figure 1). Inclusion criteria 
were diabetes duration of <6 years, age between 20-65 years, HbA1c > 6.5 % (>6.1% 
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if taking anti-diabetes agents), and BMI of 27-45kg/m2. Subjects were not recruited if 
pregnant, experienced weight loss of more than 5kg within the past 6 months or 
they have serious health problems. The majority of participants were white 
European with <2% of other ethnic minorities including Black African and South 
Asian. Most participants were on glucose lowering medication. Baseline 
characteristics of the whole direct cohort have been described (Taylor et al., 2017) 
and the baseline anthropometric, clinical and metabolic features for geographically 
defined subgroup who underwent detailed physiologic study are presented in Table 
1. 
GP practices were randomized to either Intervention or Control groups. Intervention 
group subjects stopped all anti-diabetic medication on day 1 of the Counterweight 
Plus weight management programme consisting of 825–853 kcal/d liquid formula 
diet (Cambridge Weight Plan Ltd., UK) continued for 12-20 weeks, followed by a 2-6 
week food reintroduction phase, then ongoing support for weight maintenance. The 
Control group continued usual diabetes management by their GP practice according 
to current UK clinical guidelines. 
The Tyneside cohort was designed to further study metabolic changes occurring 
during weight loss and remission of diabetes (Figure 2). Intervention group subjects 
were classified as responder or non-responder at the end of each phase. Responders 
were defined as those achieving non-diabetic levels of HbA1c (<6.5%) and blood 
glucose (<126mg/dl) off any anti-diabetes medication for at least 2 months. The 
purpose of the Control group was to examine sequential changes over the time 
course of the study in type 2 diabetic subjects, and participants (n=2) who lost >5kg 
weight and became non-diabetic were excluded from the analysis. All studies were 
performed after an overnight fast, and subjects drove or were transported to the MR 
Centre by taxi to minimise variability of physical activity and stress of travel.  
 
METHOD DETAILS 
Intraorgan fat quantification  
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All participants underwent Magnetic Resonance (MR) quantification of pancreatic 
and hepatic fat on three occasions: at baseline, following return to isocaloric eating 
after weight loss and at 12 months (Figure 2). MR data were acquired using a 3T 
Philips Achieva scanner 2 with six-channel cardiac array (Philips, Netherlands). Data 
were acquired by three-point Dixon method, with gradient-echo scans acquired 
during one breath hold (Al-Mrabeh et al., 2017). Hepatic fat content was measured 
by selecting homogenous regions of interest on five image slices of liver (Lim et al., 
2011). Intrapancreatic fat content was quantified using the MR-opsy method 
optimized to exclude interlobular adipose tissue areas (Al-Mrabeh et al., 2017). 
Analysis of pancreas fat was carried out by a single observer (AAM) in a blinded 
manner. 
 
Lipoprotein separation and VLDL1-TG Production  
VLDL1-triglyceride levels were determined from fasting plasma samples taken at 
each time point. Briefly, the VLDL1-triglyceride production rate was measured by 
accumulation of plasma VLDL1-triglyceride during competitive blockade of 
lipoprotein lipase by excess Intralipid (Al-Shayji et al., 2007). To do so, 20% Intralipid 
(Fresenius Kabi Ltd, UK) was injected intravenously as a bolus (0.1 g/kg body mass) 
followed by continuous infusion of 10% Intralipid at 0.1 g/kg/h by infusion pump 
(Arcomed Infusion Ltd, UK). Plasma samples were collected at six points over 75 min. 
After two step centrifugation, to remove blood cells then chylomicrons plus 
Intralipid particles (Scientific Laboratory Supplies Ltd, UK), the VLDL1 fraction was 
separated by ultracentrifugation at 278,000g for 98 minutes using the SW 40 Ti 
swinging-bucket rotor (Beckman Coulter, Inc, USA). Triglyceride concentration of this 
fraction was quantified using the standard method (Roche Diagnostics, UK), and 
VLDL1-triglyceride production rates were calculated from the gradient of the linear 
increase in plasma concentration over time. 
Beta cell function 
A Stepped Insulin Secretion Test with Arginine stimulation (SISTA) was used to 
quantitate first phase insulin secretion and maximal rate of insulin secretion (Lim et 
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al., 2011; Toschi et al., 2002). Square wave hyperglycemia (50.4 then 100.8 mg/dl 
above baseline) was achieved by bolus of 20% Dextrose  (Fresenius Kabi Ltd, UK) 
followed by variable 20% Dextrose infusion for each 30 minute step using an infusion 
pump (Arcomedical Infusion Ltd, UK). An arginine bolus of 5g L-Arginine 
hydrochloride 50% (Martindale Pharmaceuticals, UK) was diluted in 10 ml of 0.9% 
sodium chloride (Fresenius Kabi Ltd, UK), and injected during the second step of 
hyperglycemia to assess maximal insulin secretory capacity, followed by sampling 
every 2 min for 10 min. Blood samples for determination of C-peptide 
concentrations were obtained every 2 min for the first 10 min of each step, then 
every 5 min. Insulin secretion rates were calculated using a deconvolution method, 
modelling C-peptide kinetics (Lim et al., 2011). 
Indirect calorimetry 
Indirect calorimetry was carried out in the fasting state after 30 min of supine rest 
using a Quark ventilated hood calorimeter (COSMED, Italy).  Substrate oxidation was 
calculated using standard equations (Frayn, 1983).  
Analytical Procedures 
Glucose was measured by the oxidase method (Yellow Springs Inc., USA). HbA1c was 
quantified using HPLC (Tosoh Bioscience, UK). Liver function tests were analysed by 
standard methods at the Institute of Cardiovascular and Medical Sciences, University 
of Glasgow. C-peptide, insulin, glucose, NEFA, VLDL1-triglyceride, ketones and other 
metabolites were analysed at Clinical Pathology Accreditation Laboratory (Newcastle 
upon Tyne Hospital NHS Foundation Trust, UK) using standard kits as described in 
the key resources table.   
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Analyses were conducted on all subjects with paired data both before and after 
weight loss and weight maintenance phases. Data are presented as mean±SEM for 
normally distributed data and median (range) for skewed data as stated in the Figure 
legends and main text. Student paired or two-sample t test was used as appropriate 
for parametric data and Mann Whitney U test for nonparametric data.  All statistical 
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analyses including testing the normality of data distribution were performed  using 
Minitab 17 (Minitab Inc., USA) and a P value <0.05 was considered as significant. 
Paired data were presented in all tables, and the number of subjects in each group is 
stated in the column headings of each Table. We excluded from the analysis 6 
subjects (2 controls who lost weight and became non-diabetic, and 4 intervention 
participants who changed responder status between 5 and 12 months) 
The study was designed to compare change in parameters between responders and 
non-responders, assuming a 60% rate of return to non-diabetic glucose control and a 
25% loss to follow up. It was powered on the most stringent variable (change in 
pancreas fat) in responders compared with non-responders.  The calculated sample 
size was achieved by randomising a greater proportion of general practices to 
Intervention in the Tyneside region. As there was 69% remission of diabetes after 
weight loss and 64% at 12 months the above assumptions for statistical analysis 
were satisfied.   
 
 
 
 
